Browse studies

Find your next paid study

1,174 recruiting studies matching your filters

A 12-week Randomized, Participant and Investigator-blinded, Placebo-controlled, Exploratory Study in Adult Participants With Chronic Urticaria to Assess the Efficacy and Safety and Explore the Mechanism of Action of Remibrutinib (LOU064)

The purpose of this study is to explore the effect and Mechanism of Action (MoA) of remibrutinib (LOU064) vs. placebo on clinical outcomes in participants with…

Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT06865651

Phase 3

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Previously Untreated Chronic Lymphocytic Leukemia

The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BG…

Chronic Lymphocytic Leukemia

Estimated

~$10 – $7,500

BeOne MedicinesNCT07277231

Phase 3

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refr…

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Estimated

~$10 – $7,500

BeOne MedicinesNCT06943872

Observational

Empowering Pain Psychology Access and Collaboration (EPPAC) to Improve Treatment Engagement Among Medicaid-insured Adults With Chronic Low Back Pain: a Pilot Randomized Controlled Trial

Chronic low back pain (cLBP) is a leading cause of disability, with socioeconomically disadvantaged populations experiencing worse outcomes and lower rates of …

Chronic Low Back Pain (CLBP)

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT07843706

A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA x CD3 Bispecific Antibody) Who Receive a Kidney Transplant

The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants prev…

Chronic Kidney Disease (CKD)

Estimated

~$10 – $1,050

Regeneron PharmaceuticalsNCT05106387

Phase 2

A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with mo…

Pulmonary Disease, Chronic Obstructive

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07759245

Chronic Postsurgical Pain in Cerebral Palsy

The study purpose is to document the typical trajectory of perioperative pain experience in Cerebral Palsy (CP) and to identify important predictive factors fo…

Cerebral PalsyChronic Post Surgical Pain

Estimated

~$10 – $1,125

Chantel BurkittNCT05764681

Phase 2

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.

Chronic Myeloid Leukemia

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06236724

Phase 2

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safet…

Chronic Myeloid Leukemia

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07269470

Phase 3

A 52-week Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of u…

Chronic Pruritus of Unknown Origin

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07811869

Phase 1

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

To find the recommended doses of lisaftoclax and olverembatinib that can be given in combination with decitabine to participants with advanced CML and Ph+ AML.

Advanced Chronic Myeloid LeukemiaPhiladelphia Chromosome-Positive Acute Myeloid Leukemia

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06401603

Phase 1

A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection, for Subcutaneous Use (Once-monthly Formulation) in Adult Participants With Obesity or Overweight

This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerabi…

Chronic Weight Management

Estimated

~$10 – $8,750

Ascletis Pharma (China) Co., LimitedNCT07842640